TY - JOUR
T1 - Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors
AU - Haaker, Lorenz
AU - Tryssesoone, Loesia
AU - Renders, Inne
AU - Verbiest, Annelies
AU - Lerut, Evelyne
AU - Baldewijns, Marcella
AU - Bourgain, Claire
AU - Roussel, Eduard
AU - Van den Bulck, Heidi
AU - Wynendaele, Wim
AU - Laguerre, Brigitte
AU - Rioux-Leclercq, Nathalie
AU - Oudard, Stéphane
AU - Laenen, Annouschka
AU - Debruyne, Philip R.
AU - Albersen, Maarten
AU - Beuselinck, Benoit
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/5/17
Y1 - 2020/5/17
N2 - Objective: Papillary renal cell carcinoma (papRCC) is a rare (10%–15%) subtype of renal cancer. Few prognostic biomarkers have been described in metastatic papRCC (m-papRCC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). We aimed to study the prognostic impact of bone metastases (BM) on response rate, progression-free and overall survival (PFS and OS) in patients with m-papRCC treated with first agent VEGFR-TKIs. Patients and methods: A multicentric, retrospective analysis of patient records was conducted. BM were detected by computed tomography and/or bone scintigraphy. The International Metastatic RCC Database Consortium (IMDC) score was calculated at start of first agent VEGFR-TKI treatment. Results: Forty-nine patients were included. Best objective response was partial response in 20%, stable disease in 60% and early progressive disease in 20% of patients. Median PFS (mPFS) was 6.0 months and median OS (mOS) 14.0 months after start of first agent VEGFR-TKI. The IMDC score correlated with mOS: 77.5 months in good, 17.0 months in intermediate and 8.0 months in poor risk patients (P = 0.002). Patients with BM had a poorer outcome compared to patients without BM: mPFS was 4.0 vs. 7.0 months (P = 0.006) and mOS 7.5 vs. 19.0 months (P = 0.002). On bivariate analysis, the presence of BM was independently associated with PFS (P = 0.02) and OS (P = 0.049), independent of the IMDC risk groups. Conclusion: In m-papRCC patients treated with first agent VEGFR-TKIs, the presence of BM is an unfavorable prognostic factor, associated with shorter PFS and OS.
AB - Objective: Papillary renal cell carcinoma (papRCC) is a rare (10%–15%) subtype of renal cancer. Few prognostic biomarkers have been described in metastatic papRCC (m-papRCC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). We aimed to study the prognostic impact of bone metastases (BM) on response rate, progression-free and overall survival (PFS and OS) in patients with m-papRCC treated with first agent VEGFR-TKIs. Patients and methods: A multicentric, retrospective analysis of patient records was conducted. BM were detected by computed tomography and/or bone scintigraphy. The International Metastatic RCC Database Consortium (IMDC) score was calculated at start of first agent VEGFR-TKI treatment. Results: Forty-nine patients were included. Best objective response was partial response in 20%, stable disease in 60% and early progressive disease in 20% of patients. Median PFS (mPFS) was 6.0 months and median OS (mOS) 14.0 months after start of first agent VEGFR-TKI. The IMDC score correlated with mOS: 77.5 months in good, 17.0 months in intermediate and 8.0 months in poor risk patients (P = 0.002). Patients with BM had a poorer outcome compared to patients without BM: mPFS was 4.0 vs. 7.0 months (P = 0.006) and mOS 7.5 vs. 19.0 months (P = 0.002). On bivariate analysis, the presence of BM was independently associated with PFS (P = 0.02) and OS (P = 0.049), independent of the IMDC risk groups. Conclusion: In m-papRCC patients treated with first agent VEGFR-TKIs, the presence of BM is an unfavorable prognostic factor, associated with shorter PFS and OS.
KW - Angiogenesis inhibitors
KW - Bone metastases
KW - Papillary renal cell carcinoma
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=85084526916&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2020.04.031
DO - 10.1016/j.urolonc.2020.04.031
M3 - Article
C2 - 32430250
AN - SCOPUS:85084526916
SN - 1078-1439
VL - 38
SP - 686.e1-686.e9
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 8
ER -
